Tscan Therapeutics, Inc.
Clinical trials sponsored by Tscan Therapeutics, Inc., explained in plain language.
-
Supercharged donor cells aim to stop blood cancer relapse after transplant
Disease control Recruiting nowThis early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely reduce the risk of cancer returning after a stem cell transplant. About 75 adults with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia w…
Phase: PHASE1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
Scientists hunt for hidden triggers of autoimmune diseases
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from 300 people with autoimmune diseases like Crohn's, multiple sclerosis, and celiac disease. Researchers will look for T cells that are active in inflamed tissues to find their targets. The goal is to discover new targets for future …
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:50 UTC
-
15-Year watch begins for pioneering T-Cell therapy recipients
Knowledge-focused Recruiting nowThis study monitors up to 1,000 people who previously received an experimental T-cell therapy (TSC-100 or TSC-101) for blood cancers like AML, ALL, or MDS. Researchers will track side effects and survival for 15 years after treatment to understand the therapy's long-term safety a…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:48 UTC